pfizer
The US pharmaceutical giant Pfizer on Wednesday said its earnings for the first quarter had declined from last year but beat analysts' expectations. The company's earnings came in at $3.12 billion, or $0.55 per share. This compares with $5.54 billion, or $0.97 per share, in last year's first quarter. Excluding items, Pfizer reported adjusted earnings of $4.67 billion or $0.82 per share for the period. Analysts on average had expected the company to earn $0.52 per share, according to figures compiled by Thomson Reuters. Their estimates typically exclude special items. The company's revenue for ...
DPA International
The US pharmaceutical giant Pfizer on Wednesday said its earnings for the first quarter had declined from last year but beat analysts' expectations. The company's earnings came in at $3.12 billion, or $0.55 per share. This compares with $5.54 billion, or $0.97 per share, in last year's first quarter. Excluding items, Pfizer reported adjusted earnings of $4.67 billion or $0.82 per share for the period. Analysts on average had expected the company to earn $0.52 per share, according to figures compiled by Thomson Reuters. Their estimates typically exclude special items. The company's revenue for ...
DPA
The US pharmaceutical giant Pfizer on Wednesday said its earnings for the first quarter had declined from last year but beat analysts' expectations. The company's earnings came in at $3.12 billion, or $0.55 per share. This compares with $5.54 billion, or $0.97 per share, in last year's first quarter. Excluding items, Pfizer reported adjusted earnings of $4.67 billion or $0.82 per share for the period. Analysts on average had expected the company to earn $0.52 per share, according to figures compiled by Thomson Reuters. Their estimates typically exclude special items. The company's revenue for ...
DPA Breaking News
New York (United States) (AFP) - Pfizer reported a drop in profits on lower sales of Covid-19 related profits Wednesday as it steers investments to other pharmaceutical areas and implements previously announced cost cuts. Much lower sales of Covid-19 vaccine Comirnaty and therapeutic Paxlovid accounted for a 20 percent drop in first-quarter revenues to $14.9 billion compared with the year-ago period. Profits were $3.1 billion, down 44 percent. The drugmaker pointed to increased sales of oncology products, in part driven by the acquisition of Seagen, which was completed in December. Other produ...
AFP
Washington (AFP) - Pharmaceutical giant Pfizer has received US approval for a gene therapy against a form of hemophilia, a rare and inherited blood clotting disorder, the company said Friday. Beqvez, which is given as a single intravenous infusion, was shown in a clinical trial of 45 people to be better at preventing bleeding among adults with moderate to severe hemophilia B compared to regular infusions of a protein that promotes clotting, called protein factor IX (FIX). The current standard of care is cumbersome, requiring infusions up to several times per week. "Many people with hemophilia ...
AFP
Emblaveo, developed by Pfizer and approved today by the European Commission, can be used to treat complicated intra-abdominal and urinary tract infections, hospital-acquired pneumonia and infections caused by certain types of drug-resistant bacteria. “This newly approved medicine will fill an important gap where there are currently a very limited number of treatment options,” said the EU executive in a press release. This authorisation comes a month after the European Medicines Agency adopted a positive opinion and recommended its marketing authorisation. The antibiotic was evaluated under EMA...
Euronews (English)
New York (AFP) - Pfizer issued a disappointing 2024 forecast Wednesday, denting shares as the company navigates a profound plunge in sales tied to the Covid-19 pandemic. The company, which reported more than $100 billion in revenue in 2022 due to the lift from Covid-19 vaccine and therapeutic sales, sees 2024 revenues of between $58.5 billion and $61.5 billion, according to its presentation. Pfizer signaled it expects 2024 profits to be dented by an estimated 40 cents per share in costs to finance its acquisition of Seagen. Shares plunged more than eight percent in late-morning trading follo...
AFP
ValueWalk
New York (AFP) - Pfizer announced Tuesday that it expects to complete this week its $43 billion acquisition of cancer-focused biotech company Seagen after clearing key regulatory hurdles. "Pfizer and Seagen have now received all required regulatory approvals," Pfizer said in a news release that reported a key US antitrust waiting period had expired. "Pfizer expects to close the acquisition of Seagen on December 14." The big US drugmaker announced the transaction on March 13, pointing to Seagen's prominence in innovative cancer treatment. The purchase of Seagen "is good for patients in the batt...
AFP
Washington (AFP) - US drugmaker Pfizer on Friday said it would end a clinical trial of its developmental weight loss pill after high side effect rates caused most participants to stop using it. A twice-daily dosing of the highly anticipated drug danuglipron was found to be effective, resulting in weight reductions of between 8-13 percent at 32 weeks, compared to a placebo. But nearly three-quarters of trial participants experienced nausea, almost half had vomiting, and a quarter had diarrhea. Consequently, the discontinuation rate was greater than 50 percent, compared to 40 percent on placeb...
AFP
閲覧を続けるには、ノアドット株式会社が「プライバシーポリシー」に定める「アクセスデータ」を取得することを含む「nor.利用規約」に同意する必要があります。
「これは何?」という方はこちら